Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Withdrawal notice to <Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912]>
Iacovino ML, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, Salerno F, Olimpieri PP, Di Segni S, Sferrazza A, Piccirillo MC, Beretta GD, Pinto C, Blasi L, Cinieri S, Cavanna L, Di Maio M, Russo P, Perrone F. Iacovino ML, et al. Among authors: olimpieri pp. Lancet Reg Health Eur. 2024 Sep 2;44:101012. doi: 10.1016/j.lanepe.2024.101012. eCollection 2024 Sep. Lancet Reg Health Eur. 2024. PMID: 39444700 Free PMC article.
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.
Rigolin GM, Olimpieri PP, Summa V, Celant S, Scarfò L, Ballardini MP, Urso A, Gambara S, Cavazzini F, Ghia P, Cuneo A, Russo P. Rigolin GM, et al. Among authors: olimpieri pp. Hemasphere. 2024 Oct 8;8(10):e70017. doi: 10.1002/hem3.70017. eCollection 2024 Oct. Hemasphere. 2024. PMID: 39380844 Free PMC article.
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.
Breccia M, Celant S, Palandri F, Passamonti F, Olimpieri PP, Summa V, Guarcello A, Palumbo GA, Pane F, Guglielmelli P, Corradini P, Russo P. Breccia M, et al. Among authors: olimpieri pp. Br J Haematol. 2024 Oct 3. doi: 10.1111/bjh.19812. Online ahead of print. Br J Haematol. 2024. PMID: 39363576
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Iacovino ML, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, Salerno F, Olimpieri PP, Di Segni S, Sferrazza A, Piccirillo MC, Domenico Beretta G, Pinto C, Blasi L, Cinieri S, Cavanna L, Di Maio M, Russo P, Perrone F. Iacovino ML, et al. Among authors: olimpieri pp. Lancet Reg Health Eur. 2024 Jun 24;42:100973. doi: 10.1016/j.lanepe.2024.100973. eCollection 2024 Jul. Lancet Reg Health Eur. 2024. Retraction in: Lancet Reg Health Eur. 2024 Sep 02;44:101012. doi: 10.1016/j.lanepe.2024.101012 PMID: 39036543 Free PMC article. Retracted.
Corrigendum to "Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study" [The Lancet Regional Health - Europe 41 (2024) 100912].
Iacovino ML, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, Salerno F, Olimpieri PP, Di Segni S, Sferrazza A, Piccirillo MC, Beretta GD, Pinto C, Blasi L, Cinieri S, Cavanna L, Di Maio M, Russo P, Perrone F. Iacovino ML, et al. Among authors: olimpieri pp. Lancet Reg Health Eur. 2024 May 21;42:100940. doi: 10.1016/j.lanepe.2024.100940. eCollection 2024 Jul. Lancet Reg Health Eur. 2024. PMID: 38813536 Free PMC article.
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study.
Iacovino ML, Celant S, Tomassini L, Arenare L, Caglio A, Canciello A, Salerno F, Olimpieri PP, Di Segni S, Sferrazza A, Piccirillo MC, Beretta GD, Pinto C, Blasi L, Cinieri S, Cavanna L, Di Maio M, Russo P, Perrone F. Iacovino ML, et al. Among authors: olimpieri pp. Lancet Reg Health Eur. 2024 Apr 22;41:100912. doi: 10.1016/j.lanepe.2024.100912. eCollection 2024 Jun. Lancet Reg Health Eur. 2024. PMID: 38665620 Free PMC article.
Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1.
Sandomenico A, Selis F, Sivaccumar JP, Olimpieri P, Iaccarino E, Cicatiello V, Cantile M, Sanna R, Leonardi A, De Falco S, Ruvo M. Sandomenico A, et al. Among authors: olimpieri p. Biochem Biophys Res Commun. 2024 Jan 29;694:149417. doi: 10.1016/j.bbrc.2023.149417. Epub 2023 Dec 21. Biochem Biophys Res Commun. 2024. PMID: 38150919
Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
Arca M, Celant S, Olimpieri PP, Colatrella A, Tomassini L, D'Erasmo L, Averna M, Zambon A, Catapano AL, Russo P. Arca M, et al. Among authors: olimpieri pp. J Am Heart Assoc. 2023 Nov 7;12(21):e026550. doi: 10.1161/JAHA.122.026550. Epub 2023 Oct 18. J Am Heart Assoc. 2023. PMID: 37850449 Free PMC article.
37 results